Search

Your search keyword '"Grosset J"' showing total 197 results
Start Over Author "Grosset J" Search Limiters Full Text
197 results on '"Grosset J"'

3. Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease

Author

Martin, Christian, Maugein, J., Dailloux, M., Carbonnelle, B., Vincent, V., Grosset, J., Biologie moléculaire et cellulaire des microorganismes (EA3175), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Bactériologie, Virologie, Hygiène [CHU Limoges], CHU Limoges, and Bucek, Ingrid

Subjects
[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2005

5. The new challenges for chemotherapy research

Author

Grosset J

Subjects
medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Research, Drug administration, Leprostatic Agents, General Medicine, Pharmacology, Dapsone, medicine.disease, World Health Organization, World health, Clinical trial, Clofazimine, Leprosy, medicine, Humans, Drug Therapy, Combination, Intensive care medicine, business, Rifampicin, medicine.drug, Forecasting
Abstract

Scientific knowledge is constantly expanding, and needs are changing; therefore, efforts must be made to adapt the treatment of leprosy and the manner in which it is implemented to the newly identified needs. Because an effective vaccine against leprosy remains to be identified, multidrug therapy (MDT) is the only tool available for leprosy control. At present, therefore, the priority is to make MDT available in all endemic countries for all patients, even those living in difficult-to-access areas. The remaining important issues in chemotherapy research are to improve the quality of leprosy case-finding, improve the quality of MDT, identify the areas in which leprosy patients are not receiving proper MDT, and find the means necessary to ensure delivery to all of appropriate MDT. The MDT regimens recommended by the World Health Organization are of too long duration, require correct classification of the patients as PB or MB, and rely upon the daily self-administration of dapsone and clofazimine to prevent selection of rifampicin resistant mutants among MB patients. Thus, research leading to the development of new drug regimens should be directed toward overcoming the shortcomings of the presently recommended regimens. The drugs required to permit use of regimens of shorter duration, that may be employed among both PB and MB patients, and that enable fully supervised drug administration may be already in hand, and the necessary clinical trials to confirm efficacy and acceptability should be carried out.

Published
2001

6. Country assessment reports

Author

Grosset, J., Kanga, J. M., Portaels, F., Guédénon, A., Tignokpa, N., Scherpbier, R., Asiedu, K., Asiedu, K., Scherpbier, R., and Raviglione, M.

Subjects
Surveillance, Côte d'Ivoire, Africa, West, Mycobacterium ulcerans, Togo, Bacterial diseases, Prevalence, Benin, Financing, National, Ghana, Buruli ulcer, Control programs
Published
2000

7. Rapports des évaluations dans les pays

Author

Grosset, J., Kanga, J. M., Portaels, F., Guédénon, A., Tignokpa, N., Scherpbier, R., Asiedu, K., Asiedu, K., Scherpbier, R., and Raviglione, M.

Subjects
Mycobacterium ulcerans, Bacterial diseases, Prevalence, Financing, National, Buruli ulcer, Control programs
Published
2000

8. Genomics and the chemotherapy of leprosy

Author

Grosset, J H, Cole, S T, Grosset, J H, and Cole, S T

Abstract

The information deduced from the genome sequence of Mycobacterium leprae is of immense value for the chemotherapy of leprosy. Knowing the complete set of genes, enzymes and proteins allows us to understand why some drugs are without effect whereas others are fully active. It may also enable better use to be made of existing drugs, such as beta-lactams, and opens new avenues for the development of novel compounds. M. leprae is relatively susceptible to a wide range of drugs, unlike the highly related tubercle bacillus, and several new multidrug regimens are in clinical trials. Genomics provides a number of possible explanations for this broader susceptibility as some of the genes encoding enzymes involved in antibiotic inactivation have decayed whereas the number of transporters available to contribute to drug efflux is considerably lower than in Mycobacterium tuberculosis. Several leads for new drug targets have been uncovered.

Published
2010

11. Gene expression in mesophyll protoplasts

Author

Meyer, Y., Chartier, Y., Grosset, J., Marty, J., Brugidou, Christophe, Marinho, P., Rivera, R., Roubelakis-Angelakis, K.A. (ed.), and Tran Thanh Van, K. (ed.)

Subjects
DEVELOPPEMENT, PROTEINE, PHYSIOLOGIE VEGETALE, GENETIQUE, GENE, PROTOPLASTE, FEUILLE
Published
1993

14. Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans

Author

Etuaful, S., primary, Carbonnelle, B., additional, Grosset, J., additional, Lucas, S., additional, Horsfield, C., additional, Phillips, R., additional, Evans, M., additional, Ofori-Adjei, D., additional, Klustse, E., additional, Owusu-Boateng, J., additional, Amedofu, G. K., additional, Awuah, P., additional, Ampadu, E., additional, Amofah, G., additional, Asiedu, K., additional, and Wansbrough-Jones, M., additional

Published
2005
Full Text
View/download PDF

28. Evolution de la sensibilité des bacilles à Gram négatif à la ceftazidime et à trois autres bêta-lactamines en milieu hospitalier de 1989 à 1993

Author

Thabaut, A., primary, Avril, J.-L., additional, Bébéar, C., additional, Bergogne-Bérezin, E., additional, Boucot, I., additional, Chiche, D., additional, Cluzel, R., additional, Jarlier, V., additional, Grosset, J., additional, Lemeland, J.-F., additional, Meyran, M., additional, Monteil, H., additional, Morel, C., additional, Nicolas, M.-H., additional, Philippon, A., additional, Reverdy, M.-E., additional, and Sirot, J., additional

Published
1995
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results